AbstractObjective To analyze the effects of donepezil hydrochloride combined with memantine hydrochloride on cognitive function in patients with Alzheimer's disease（AD）. Methods 86 cases of patients with AD were selected,and all of them were randomly divided into an experimental group and a conventional group,with 43 patients in each group.The conventional group was given low-dose donepezil hydrochloride,and the experimental group was combined with memantine hydrochloride on the basis of the conventional group.The curative effect,the Alzheimer's disease behavioralpathology scale（BEHAVE-AD）score,the Alzheimer's Disease Assessment Scale（ADAS-cog）,Mini Mental State Assessment Scale（MMSE）,the inflammatory factors [interleukin-6（IL-6）,tumor necrosis factor-α（TNF-α）,C-reactive protein（CRP）] levels and the occurrence rate of adverse reactionsof the two groups were compared. Results The total effective rate 93.02%（40/43）of the experimental group washigher than 72.09%（31/43）of the conventional group（P<0.05）;After treatment,the BEHAVE-AD score of the experimental group was lower than that of the conventional group（P<0.05）;After treatment,the ADAS-cog score of the experimental group was lower than that of the conventional group,while the MMSE score was higher than that of the conventional group（P<0.05）;After treatment,the levels of IL-6,TNF-α and CRP in the experimental groupwereall respectivelylower than thosein the conventional group（P<0.05）;The occurrence rate of adverse reactions of the experimental group was 6.98%（3/43）,which was not significantly different from that of the conventional group11.63%（5/43）（P>0.05）. Conclusion The combination of donepezil hydrochloride and memantine hydrochloride for AD patientshas a significant effect,which can improve the clinical symptoms,cognitive function and mental state,alleviate the inflammatory reactions,and has the safety.
Liu Fan,Liu Xiaopeng,Zhou Yu. Effects of Low-dose Donepezil Hydrochloride Combined with Memantine Hydrochloride on Cognitive Function in Patients with Alzheimer’s Disease[J]. journal1, 2024, 44(1): 17-19.
2024, Vol. 44 
